nicotinic acetylcholine receptor
Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment.
Rochester, United States. In Lancet Neurol, Apr 2015
Most CMS stem from molecular defects in the muscle nicotinic acetylcholine receptor, but they can also be caused by mutations in presynaptic proteins, mutations in proteins associated with the synaptic basal lamina, defects in endplate development and maintenance, or defects in protein glycosylation.
Cytisine versus nicotine for smoking cessation.
Auckland, New Zealand. In N Engl J Med, 2015
BACKGROUND: Placebo-controlled trials indicate that cytisine, a partial agonist that binds the nicotinic acetylcholine receptor and is used for smoking cessation, almost doubles the chances of quitting at 6 months.